Introduction

Polymyxin B sulfate, classified as a cationic polypeptide antibiotic, is one of the last lines of defense against multidrug-resistant Gram-negative bacteria. It was first isolated in the late 1940s, but due to its nephrotoxic and neurotoxic side effects, its use was initially limited. However, with the rise of resistant bacterial strains, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, Polymyxin B sulfate has re-emerged as a critical therapeutic option.

Chemically, Polymyxin B sulfate is composed of two main components: polymyxin B1 and polymyxin B2, which act synergistically to disrupt bacterial cell membranes. Its primary mechanism of action involves binding to lipopolysaccharides (LPS) in the outer membrane of Gram-negative bacteria, leading to increased membrane permeability and cell death. This distinctive mechanism is crucial for targeting pathogens that other antibiotics cannot reach.

Figure 1 Characteristics of Polymyxin B sulfate

Properties of Polymyxin B Sulfate

Understanding the chemical and physical properties of Polymyxin B sulfate is critical for professionals working with this compound. As a sulfate salt of polymyxin B, it is highly soluble in water, forming a clear, slightly acidic solution. It is typically available in powder form, which can be reconstituted into a solution for intravenous, intramuscular, or topical applications.

Chemically, Polymyxin B sulfate is a mixture of polymyxins, which are cyclic polypeptides containing several amino acids. It has a molecular weight of approximately 1,200 Daltons. The molecule's amphipathic nature, meaning it contains both hydrophilic and hydrophobic regions, is what allows it to effectively interact with bacterial membranes.

Some of its key properties include:

Molecular Formula: C56H98N16O13S

Solubility: Freely soluble in water and saline; insoluble in organic solvents such as ethanol and acetone.

pH: The aqueous solution typically has a pH of 5.0–6.5, depending on concentration.

Stability: It is relatively stable in acidic environments but can degrade in alkaline conditions. Exposure to high temperatures and moisture can also lead to the degradation of the compound.

Main Components

Polymyxin B sulfate is primarily composed of two main polymyxins: polymyxin B1 and polymyxin B2. Both of these components share a common cyclic heptapeptide core structure but differ slightly in their fatty acyl side chains, leading to minor differences in their lipophilicity and biological activity. These two components typically exist in a ratio of approximately 70% polymyxin B1 and 30% polymyxin B2.

The antimicrobial activity of these components stems from their ability to target and disrupt the integrity of the bacterial cell membrane. By binding to lipopolysaccharides (LPS) and phospholipids in the outer membrane of Gram-negative bacteria, polymyxin B destabilizes the membrane, causing leakage of cellular contents and subsequent bacterial death. This action is highly effective against bacteria with resistant outer membrane structures, such as Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii.

Uses of Polymyxin B Sulfate

Polymyxin B sulfate is primarily used to treat infections caused by multidrug-resistant Gram-negative bacteria. Its clinical applications are diverse, ranging from topical treatments for superficial infections to intravenous administration for severe systemic infections.

Topical Applications: Polymyxin B sulfate is a common ingredient in topical antibiotic ointments and creams, often combined with other antibiotics such as bacitracin and neomycin. These formulations are used to treat localized skin infections, burns, and wounds. Its ability to disrupt bacterial membranes makes it particularly useful for preventing infections in compromised skin areas.

Intravenous Administration: For more serious infections, such as bacteremia, pneumonia, and urinary tract infections caused by multidrug-resistant pathogens, Polymyxin B sulfate is administered intravenously. In these cases, the dosage must be carefully monitored due to its potential nephrotoxicity and neurotoxicity.

Inhalation Therapy: In certain cases, particularly in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, Polymyxin B sulfate can be administered via inhalation. This form of delivery targets the respiratory tract directly, providing a higher concentration of the drug to the site of infection while minimizing systemic exposure.

Combination Therapy: Due to its unique mechanism of action, Polymyxin B sulfate is often used in combination with other antibiotics to enhance its efficacy and reduce the likelihood of resistance development. For example, it is sometimes paired with carbapenems or aminoglycosides in severe infections.

Storage and Handling

Proper storage and handling of Polymyxin B sulfate are crucial to maintaining its efficacy. As a hygroscopic powder, it must be stored in a tightly sealed container to prevent moisture absorption, which can lead to degradation. The ideal storage conditions are in a cool, dry place, away from direct sunlight and heat.

Once reconstituted into a solution, Polymyxin B sulfate should be used immediately or stored at a controlled temperature (2-8°C) and used within 24 hours to prevent degradation. It is important to note that reconstituted solutions are sensitive to both light and temperature, so they should be protected from excessive exposure to either.

Pharmacies and medical facilities often handle Polymyxin B sulfate in its powder form, reconstituting it on an as-needed basis for clinical use. Proper personal protective equipment (PPE) is recommended during handling to avoid potential respiratory exposure to the powder, as well as skin or mucous membrane contact.

Conclusion

Polymyxin B sulfate remains a critical component of the modern antibiotic arsenal, especially in the fight against multidrug-resistant Gram-negative infections. Despite its potential for toxicity, its unique mechanism of action and effectiveness against otherwise untreatable infections underscore its value in clinical practice.

As antibiotic resistance continues to rise globally, the importance of compounds like Polymyxin B sulfate will only increase. However, due to its toxicity, the use of this drug must be carefully controlled, with regular monitoring to minimize adverse effects. Additionally, further research into minimizing its side effects while enhancing its efficacy is necessary to ensure its continued relevance in the fight against bacterial infections.

Reference

[1] Evans M E, Feola D J, Rapp R P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria[J]. Annals of Pharmacotherapy, 1999, 33(9): 960-967.

[2] Corrigan J J, Kiernat J F. Effect of polymyxin B sulfate on endotoxin activity in a gram-negative septicemia model[J]. Pediatric Research, 1979, 13(1): 48-51.